Global Metastatic Solid Tumors Market, By Types (Sarcomas, Carcinomas and Lymphomas), Treatment (Chemotherapy Drug, Immunotherapy Drug, Targeted Therapy and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Metastatic Solid Tumors Market Analysis and Size
Metastasis results for 90% of cancer-associated mortality and only a small number of patients with metastatic cancer can be treated with traditional strategies such as chemotherapy, radiotherapy and surgical removal. Metastatic tumors are difficult to treat with conventional therapy because of their anatomically diffuse localization and resistance to cytotoxic agents. In addition to this, rapid technological advancements in imaging and cancer cell identification have expressively improved understanding of cancer metastasis.
Data Bridge Market Research analyses a growth rate in the global metastatic solid tumors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Metastatic Solid Tumors Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Types (Sarcomas, Carcinomas and Lymphomas), Treatment (Chemotherapy, Immunotherapy, Targeted Therapy and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India)
Solid tumors are created by the addition of aberrant tissues which do not contain any liquid or cyst in the case of cancer. There are two types of solid tumors, namely benign and malignant. Metastatic solid tumors are abnormal mass of tissue that generally does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them. Few examples of solid tumors are sarcomas, carcinomas, and lymphomas.
Global Metastatic Solid Tumors Market Dynamics
- Increasing prevalence of different forms of metastatic cancers
The rising prevalence of different forms of metastatic cancer is estimated to enhance the market's growth. In 2012, WHO projected that 8.2 million people died globally as a result of various types of malignancies. Lung, colorectal, breast, and liver cancers were among the most common cancers, with lung, colorectal, and breast cancers being the most common. Brain tumors (medulloblastoma and glioma) and neuroblastoma are the most frequent solid tumors; rhabdomyosarcoma and osteosarcoma are less common solid cancers.
- Higher Demand for Oral Drugs
Oral drugs is estimated to boost the market growth. The segment is anticipated to enhance the global market as most products are available in capsule and tablet form and it is a very convenient route of administration.
- Increase in Hospital Demand
The treatment of metastatic solid tumor is primarily performed in hospitals due to the strict guidelines. Prolonged post-treatment hospitalization period and increased morbidity of gastrointestinal stromal tumor continue to boost the presence of hospitals. By the end of 2026, more than US$ 480 Mn worth of revenues will be produced from treating GISTs in hospitals worldwide. During the forecast period, specialized cancer treatment centers will also emerge as a main end-user in the global metastatic solid tumor market.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for treating metastatic solid tumor are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
- Increasing Demand for Chemotherapy
Treatment of metastatic solid tumor is a multidisciplinary approach, involving the contribution of medical oncologists, surgeons, radiologist, as well as pathologists. So far, radiotherapy's role in treating metastatic solid tumor remains determinedly unestablished. Most patients suffering from this tumor choose symptomatic treatments such as conventional chemotherapy as surgery is not possible in most cases. Thus, this factor create much opportunity for the market growth.
- Availability of Fake Drugs
The increasing availability of fake and misbranded drugs is considered to be a significant restraint. Consequently, it can create confusion and hamper the global metastatic solid tumors market value.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. The treatment procedures such as chemotherapy, radiation therapy, targeted therapy restrict the market growth.
This global metastatic solid tumors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global metastatic solid tumors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In May 2021, Amgen announced the U.S. FDA approval for LUMAKRAS used for treating adult patients suffering from KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS was given priority approval because of its high overall response rate (ORR) and short response time.
Global Metastatic Solid Tumors Market Scope
The global metastatic solid tumors market is segmented on the basis of types, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Targeted Therapy
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Metastatic Solid Tumors Market Regional Analysis/Insights
The global metastatic solid tumors market is analyzed and market size insights and trends are provided by types, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global metastatic solid tumors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to increased prevalence of cancer and related disorders and number of generic drugs.
North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Metastatic Solid Tumors Market Share Analysis
The global metastatic solid tumors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global metastatic solid tumors market.
Key players operating in the global metastatic solid tumors market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)